<DOC>
	<DOCNO>NCT00851409</DOCNO>
	<brief_summary>Hereditary angioedema ( `` HAE '' ) disease characterize recurrent tissue swell affect various body location . Recent literature show patient frequent attack may benefit long-term prophylaxis . This study aim evaluate safety prophylactic effect weekly administration 50 IU/kg recombinant C1 Inhibitor ( `` rhC1INH '' ) .</brief_summary>
	<brief_title>A Study Safety Immunogenicity Repeated rhC1INH Administration</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Aged least 18 year Signed informed consent Comfirmed diagnosis HAE baseline plasma level functional C1INH activity le 50 % normal , and/or proven HAE , mutation C1INH gene . A history anaphylaxis severe allergy ( i.e . require medication ) food , proteins and/or drug . A history allergic reaction C1INH product rabbit protein . Any report SAE related study drug administration ( withdrawal criterium ) Elevated IgE rabbit dander ( &gt; 0.35 kU/L ; ImmunoCap assay ; Phadia ) A diagnosis acquire C1INH deficiency . Woman child bear potential , pregnancy breastfeed previous treatment within last 3 month plasmaderived C1INH Any clinically significant abnormality routine haematology , biochemistry urinalysis Any condition treatment opinion investigator might interfere evaluation study objective . Any change since screen would exclude subject base exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>